肺癌中枢神经系统播散的管理:现状与前沿
脑转移在非小细胞肺癌和小细胞肺癌中均常见,近十年放疗与肿瘤内科进展显著。放疗研究聚焦于扩大立体定向放射外科适应人群、降低全脑放疗毒性并优化患者选择,以及小细胞肺癌中不预防性颅脑照射的脑磁共振监测、海马保护等;内科方面多款酪氨酸激酶抑制剂及免疫检查点抑制剂显示中枢活性,为多学科策略开辟新途径。
要点
- 脑转移在非小细胞肺癌和小细胞肺癌中均常见
- 立体定向放射外科扩大脑转移局部治疗候选人群
- 部分酪氨酸激酶抑制剂和免疫检查点抑制剂显示中枢活性
核心结论
- 近十年放疗和肿瘤内科进展使脑转移管理取得实质进步,未来研究将聚焦靶向和免疫治疗中枢活性的更可靠表征及多学科策略的优化整合与患者选择。
研究设计与样本
- 本文为综述,总结脑转移管理的放疗与内科治疗进展及未来研究方向。
主要发现
- 近期及正在进行的放疗试验聚焦于通过立体定向放射外科扩大脑转移局部治疗的候选人群、降低全脑放疗毒性并改善患者选择。
- 在小细胞肺癌中,评估不预防性颅脑照射下的脑磁共振监测、预防性颅脑照射和全脑放疗中的海马保护以及脑转移 upfront 立体定向放射外科的作用。
- 肿瘤内科方面,多种具有中枢神经系统活性的酪氨酸激酶抑制剂的开发以及免疫检查点抑制剂在部分患者中中枢神经系统活性的新数据,为脑转移管理的新型全身和多学科治疗策略打开了大门。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Brain metastases (BrM) are common in both non-small-cell lung cancer and small-cell lung cancer. Substantial progress in BrM management has occurred in the past decade related to advances in both radiation and medical oncology. Recent and ongoing radiation trials have focused on increasing the candidacy for focal therapy of BrM with stereotactic radiosurgery; reducing the toxicity and improving patient selection for whole brain radiotherapy; and, in small-cell lung cancer, evaluating brain magnetic resonance imaging surveillance without prophylactic cranial irradiation, hippocampal avoidance in prophylactic cranial irradiation and whole brain radiotherapy, and the role of upfront stereotactic radiosurgery for BrM. In medical oncology, the development of multiple tyrosine kinase inhibitors with encouraging CNS activity and emerging data on the CNS activity of immune checkpoint inhibitors in some patients have opened the door to novel systemic and multidisciplinary treatment strategies for the management of BrM. Future research will focus on more robust characterizations of the CNS activity of targeted therapy and immunotherapies, as well as optimal integration and patient selection for multidisciplinary strategies involving CNS-active drugs, radiation therapy, and CNS surveillance.
引用
- Tsui DCC, Camidge DR, Rusthoven CG, et al. Managing Central Nervous System Spread of Lung Cancer: The State of the Art. J Clin Oncol. 2022. PMID: 34985937. doi:10.1200/JCO.21.01715
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。